Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.

ABSTRACT:

Background

Reductions in transfusion requirements/improvements in hematologic parameters have been associated with iron chelation therapy in transfusion-dependent patients, including those with myelodysplastic syndromes; data on there reductions/improvements have been limited to case reports and small studies.

Design and methods

To explore this observation in a large population of patients, we report a post-hoc analysis evaluating hematologic response to deferasirox in a cohort of iron-overloaded patients with myelodysplastic syndromes enrolled in the Evaluation of Patients' Iron Chelation with Exjade(®) (EPIC) study using International Working Group 2006 criteria.

Results

Two-hundred and forty-seven, 100 and 50 patients without concomitant medication for myelodysplas

SUBMITTER: Gattermann N 

PROVIDER: S-EPMC3436237 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature